<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<pubmed-document>
<record>
<header>
<identifier>22119277</identifier>
<setSpec>1885-1398</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:author>Pedroza Granados, Jorge</dc:author>
<dc:author>Zúñiga Varga, Javier</dc:author>
<dc:author>Dábague Guzmán, Janet</dc:author>
<dc:description xml:lang="en">ANCA-associated vasculitides are rare and complex systemic diseases. Collaborative studies in both Europe and the United States of America have been particularly important in the development of randomized clinical trials that have studied the safety of maintenance therapy for these diseases. Although cyclophosphamide continues to be the main drug utilized during induction therapy, its long-term side effects have given rise to the study of other immunosuppressive drugs for the maintenance phase. We herein review these studies with particular attention to combination therapy and the duration of treatment.</dc:description>
<dc:type>English Abstract</dc:type>
<dc:language>es</dc:language>
<dc:date>2011 Dec </dc:date>
<dc:title xml:lang="es">Tratamiento de mantenimiento en las vasculitis asociadas a anticuerpos contra citoplasma de neutrófilos (ANCA).</dc:title>
<dc:title xml:lang="en">[Maintainance treatment of anti-neutrophil cytoplasm associated antibodies (ANCA)].</dc:title>
<dc:publisher>Reumatologia clinica</dc:publisher>
</metadata>
</record>
</pubmed-document>
